Tatt:
Good article. For me, this part of the second article was encouraging:
>>>>>>>>>>>
Recently, data on OS and SRT have become available. Interestingly, Trock et al showed in a group of men with a median follow-up of 9 yr after prostatectomy that the benefit of SRT for PCa-specific mortality was particularly seen in men with a PSA DT <6 mo who obtained SRT to the prostate fossa within 2 yr after a PSA rise [11]. These data suggest that local disease control may prolong PCa-specific survival in men formerly thought to be at risk for systemic disease progression and less likely to benefit from (salvage) RT. This finding may possibly be explained by the fact that men with slowly progressing disease—although at risk of systemic progression—may not benefit from SRT because the risk of development of lethal PCa in these cases may be low. Certainly, longer follow-up is needed to answer this question, but it seems in line with findings in, for example, breast cancer
>>>>>>>>>>>>>>>
Mel